Role of perfluorochemical emulsions in the treatment of myocardial reperfusion injury

American Heart Journal

Volumn 124, Issue 5, 1992, Pages 1347-1357

  Forman, Mervyn B ^a   Ingram, David A ^a   Murray, John J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOSOL; PERFLUORO COMPOUND;

CORONARY ARTERY BLOOD FLOW; DOG; HEART FAILURE; INTRAARTERIAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

ANIMAL; COMPLEMENT; DOGS; EMULSIONS; ENDOTHELIUM, VASCULAR; FLUOROCARBONS; HUMAN; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NEUTROPHILS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026463996     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/0002-8703(92)90422-R     Document Type: Article

References (82)

1. The wavefront phenomenon of ischemic cell death. I. Myocardial infarct size vs. duration of coronary occlusion in dogs
2. The “wavefront phenomenon” of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow
3. Experimental infarct size as a function of the amount of myocardium at risk
4. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
5. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET)
6. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial
7. Randomized trial of intravenous streptokinase oral aspirin both or neither among 17 187 cases of suspected acute myocardial infarction
8. The stunned myocardium: prolonged, post-ischemic ventricular dysfunction
9. Oxygen-derived free radicals and post-ischemic myocardial dysfunction (“stunned myocardium”)
10. Reperfusion of the ischemic myocardium
11. Myocardial reperfusion: a doubleedged sword?
12. Pathogenesis and modification of myocardial reperfusion injury
13. Endothelial and myocardial injury during ischemia and reperfusion. Pathogenesis and therapeutic implications
14. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the “no-reflow” phenomenon
15. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model
16. Changes in the microvascularization of ischemic and infarcted myocardium
17. The “no-reflow” phenomenon after temporary occlusion in the dog
18. Progressive impairment of regional myocardial perfusion after initial restoration of post-ischemic blood flow
19. Role of leukocytes in the response to acute myocardial ischemia and reflow in dogs
20. Presevation of endothelial cell structure and function by intracoronary perfluorochemical in a canine preparation of reperfusion
21. Coronary vascular reactivity after acute myocardial ischemia
22. Experimental acute myocardial infarction. Histologic and histochemical studies of early myocardial infarcts induced by temporary or permanent occlusion of a coronary artery
23. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals: role of neutrophil activation
24. Myocardial neutrophil accumulation during reperfusion after reversible or irreversible ischemic injury
25. Neutrophil accumulation in ischemic myocardium: insights into time course, distribution and mechanism of localization during early reperfusion
26. The respiratory burst of phagocytes
27. Neutrophil degranulation
28. Role of oxygen in the cellular damage induced by re-oxygenation of hypoxic heart
29. Oxygen-mediated myocardial damage during ischaemia and reperfusion: role of the cellular defenses against oxygen toxicity
30. In vitro suppression serum elastase-inhibitory capacity by reactive oxygen species generated by phagocytosing polymorphonuclear leukocytes
31. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog
32. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs
33. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function
34. Canine neutrophil activation by cardiac lymph obtained during reperfusion of ischemic myocardium
35. Ryan J. Fc and C3b receptors on pulmonary endothelial cells: induction by injury
36. Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle
37. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induces biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells
38. Endothelial leukocyte adhesion molecule: an inducible receptor for neutrophils related to complement regulatory proteins and lectins
39. Leukocyte-endothelial interactions
40. The vascular endothelium: a survey of some newly evolving biochemical and physiological features
41. Endothelial cells: not just a cellophane wrapper
42. Adenine nucleotide and adenosine metabolism in cultured coronary endothelial cells: formation and release of adenine compounds and possible functional implications
43. Survival of mammals breathing organic liquids equilibrated with oxygen at atmosphere pressure
44. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol®-DA
45. Clinical studies of a perfluorochemical whole blood substitute (Fluosol®-DA). Summary of 186 cases
46. Fluorocarbon-polyol artificial blood substitutes
47. Perfluorochemicals: blood substitutes and beyond
48. Blood substitutes: where do we stand with the fluorocarbon approach?
49. Fluorocarbons: current status and future applications
50. Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol®-DA 20%
51. Reduction of myocardial ischemia during percutaneous coronary angioplasty with oxygenated Fluosol®
52. Effects of intravenous fluorocarbons during and without oxygen enhancement on acute myocardial ischemic injury assessed by measurement of intramyocardial gas tensions
53. Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia
54. Reduction of infarct size with intracoronary perfluorochemical in a canine preparation of reperfusion
55. Beneficial long-term effects of intracoronary perfluorochemical on infarct size and ventricular function in a canine reperfusion model
56. Reduction in reperfusion injury by blood-free reperfusion after experimental myocardial infarction
57. Pharmacologic perturbation of neutrophils by Fluosol® results in a sustained reduction in infarct size in the canine model of reperfusion
58. Effect of perfluorochemical Fluosol®-DA on myocardial infarct healing in the rabbit
59. Prevention of neutrophil-mediated injury to endothelial cells by perfluorochemical
60. Fluosol® activates human neutrophils via phagocytosis: a novel therapy for reducing reperfusion injury
61. Immunological biocompatibility in blood substitutes
62. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanisms of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis
63. Pulmonary complications after Fluosol® administration to patients with lifethreatening blood loss
64. Hemodynamic profile of adverse clinical reactions to Fluosol®-DA 20%
65. Phase I/II study of Fluosol®-DA and 100% oxygen as an adjuvant to radiation in the treatment of advanced squamous cell tumors of the head and neck
66. Purification of Pluronic F-68 for perfluorochemical emulsification
67. Reduction in the toxicity of a component of an artificial blood substitute by supercritical fluid fractionation
68. Complement activation by Fluosol® may contribute to its beneficial effect in myocardial reperfusion injury [Abstract]
69. Complement activation by artificial blood substitute Fluosol®: in vitro and in vivo studies
70. The Italian Group for the Study of Streptokinase in Myocardial Infarct: analysis of intrahospital causes of health
71. A randomized, double-blind, controlled pilot trial of combined early intravenous captopril and t-PA therapy in acute myocardial infarction [Abstract]
72. Combined tissue type plasminogen activator and prostacyclin therapy for acute myocardial infarction
73. A randomized, double-blind trial of recombinant human superoxide dismutase (SOD) in patients undergoing PTCA for acute MI [Abstract]
74. Demonstration of myocardial reperfusion injury in man results of a pilot study utilizing acture angioplasty with perfluorochemical in anterior myocardial infarction
75. Mummification of the infarcted myocardium by high dose corticosteroids
76. Effects of corticosteroids on myocardial infarct size and healing following experimental coronary occlusion
77. Effects of potential blood substitutes (perfluorochemicals) on rat liver and spleen
78. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion
79. ®) reduces myocardial infarct size in dogs [Abstract]
80. Identification of a time window for therapy to reduce experimental canine myocardial injury: suppression of neutrophil activation during 72 hours of reperfusion
81. Poloxamer 188, a hemorrheologic agent, reduces experimental myocardial infarct size: importance of prolonged therapy for reperfusion injury [Abstract]
82. The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo